Adding a new drug to an advanced cell therapy for aggressive blood cancer

This trial is testing whether nemtabrutinib, a daily pill, can be safely combined with lisocabtagene maraleucel—an advanced cell therapy already approved for treating advanced chronic lymphocytic leukemia. The study involves about 20 patients whose cancer has come back or stopped responding to previous treatments. Researchers want to see if adding the medication to the cell therapy helps more patients achieve and maintain remission.

Chronic lymphocytic leukemia can return or become resistant to treatment, leaving patients with limited options. This medication has shown promise in blood cancers, and researchers believe combining it with the existing cell therapy might improve how well the treatment works and how long its benefits last.